Driehaus Capital DAWN Position
Exited6-Fund ConvergenceDriehaus Capital exited their position in Day One Biopharmaceuticals Inc. (DAWN) in Q4 2024, after holding the stock for 8 quarters.
The position was first reported in Q1 2023 and has been tracked across 8 quarterly 13F filings.
DAWN is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Tovorafenib in 412 days (May 31, 2027), making the timing of Driehaus's position particularly relevant.
Short interest stands at 11.6% of float with 1.1 days to cover, indicating significant bearish positioning against the stock.
About Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
11.6%
1.1 days to cover
Driehaus Capital DAWN Position History
Frequently Asked Questions
Does Driehaus Capital own DAWN?
No. Driehaus Capital exited their position in Day One Biopharmaceuticals Inc. (DAWN) in Q4 2024. They previously held the stock for 8 quarters.
How many hedge funds own DAWN?
6 specialist biotech hedge funds currently hold DAWN, including RA Capital Management, Deerfield Management, Boxer Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy DAWN?
Driehaus Capital's position in DAWN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's DAWN position increasing or decreasing?
Driehaus Capital completely exited their DAWN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DAWNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →